These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1118 related items for PubMed ID: 16322295

  • 1. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
    Clin Cancer Res; 2005 Dec 01; 11(23):8348-57. PubMed ID: 16322295
    [Abstract] [Full Text] [Related]

  • 2. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.
    J Clin Oncol; 2005 Jul 01; 23(19):4287-97. PubMed ID: 15994142
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
    Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S.
    Am J Clin Pathol; 2008 Apr 01; 129(4):563-70. PubMed ID: 18343783
    [Abstract] [Full Text] [Related]

  • 6. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.
    Taiwan J Obstet Gynecol; 2007 Jun 01; 46(2):146-51. PubMed ID: 17638622
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT.
    Clin Cancer Res; 2008 Dec 01; 14(23):7861-70. PubMed ID: 19047115
    [Abstract] [Full Text] [Related]

  • 10. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
    Cuadros M, Cano C, López FJ, López-Castro R, Concha A.
    Pathobiology; 2013 Dec 01; 80(1):32-40. PubMed ID: 22832278
    [Abstract] [Full Text] [Related]

  • 11. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL, Jamehdor MR, Arber JM.
    Mod Pathol; 2000 Aug 01; 13(8):866-73. PubMed ID: 10955453
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
    Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S.
    J Mol Diagn; 2004 Feb 01; 6(1):42-51. PubMed ID: 14736826
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.
    Pol J Pathol; 2004 Feb 01; 55(4):165-71. PubMed ID: 15757204
    [Abstract] [Full Text] [Related]

  • 16. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C.
    Histopathology; 2005 Apr 01; 46(4):431-41. PubMed ID: 15810955
    [Abstract] [Full Text] [Related]

  • 17. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y, Booser DJ, Sneige N.
    Cancer; 2005 May 01; 103(9):1763-9. PubMed ID: 15786420
    [Abstract] [Full Text] [Related]

  • 18. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C, von Struensee D, Bierer S, Bögemann M, Hertle L, Eltze E.
    Aktuelle Urol; 2005 Sep 01; 36(5):423-9. PubMed ID: 16163605
    [Abstract] [Full Text] [Related]

  • 19. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X.
    Mod Pathol; 2000 Nov 01; 13(11):1238-43. PubMed ID: 11106082
    [Abstract] [Full Text] [Related]

  • 20. Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.
    Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E.
    Scand J Clin Lab Invest; 2004 Nov 01; 64(5):511-22. PubMed ID: 15276916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.